By immunotargeting CD31, we specifically delivered ORI to endothelial cells, where ORI was released and bound to Keap1 to inhibit ROS and IL-6 expression and suppress ALI and ARDS. This evidence concerns the gene IL6 and acute respiratory distress syndrome.